A detailed history of Exane Asset Management transactions in Biogen Inc. stock. As of the latest transaction made, Exane Asset Management holds 5,000 shares of BIIB stock, worth $732,350. This represents 0.9% of its overall portfolio holdings.

Number of Shares
5,000
Holding current value
$732,350
% of portfolio
0.9%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 05, 2024

BUY
$189.07 - $236.8 $945,350 - $1.18 Million
5,000 New
5,000 $969,000
Q3 2018

Nov 16, 2018

SELL
$293.51 - $383.83 $11.9 Million - $15.6 Million
-40,708 Closed
0 $0
Q2 2018

Sep 06, 2018

BUY
$257.52 - $306.91 $608,519 - $725,228
2,363 Added 6.16%
40,708 $0
Q1 2018

Apr 30, 2018

SELL
$260.13 - $367.91 $9.9 Million - $14 Million
-38,051 Reduced 49.81%
38,345 $0
Q4 2017

Feb 08, 2018

BUY
$307.64 - $344.58 $445,462 - $498,951
1,448 Added 1.93%
76,396 $0
Q3 2017

Oct 13, 2017

BUY
$281.15 - $329.69 $21.1 Million - $24.7 Million
74,948
74,948 $23.5 Billion

Others Institutions Holding BIIB

About BIOGEN INC.


  • Ticker BIIB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 144,000,992
  • Market Cap $21.1B
  • Description
  • Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...
More about BIIB
Track This Portfolio

Track Exane Asset Management Portfolio

Follow Exane Asset Management and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Exane Asset Management, based on Form 13F filings with the SEC.

News

Stay updated on Exane Asset Management with notifications on news.